TCD's leading target is Choline Kinase Alpha (ChoKα), an enzyme regulating the production of phosphatidylcholine (a key building block in the formation of the cell's membrane).

TCD has demonstrated that ChoKα is a treatment target of unique quality. Not only can ChoKα be used for treatment of patients suffering from a broad variety of tumors, but also the inhibition of ChoKα while merely arresting temporarily the life cycle of normal cells is toxic to cancer cells.

With ChoKα TCD is implementing a novel approach of exploiting phospholipid metabolism for the treatment of cancer using a Personalized and Targeted treatment strategy.

All rights reserved. 2011 TCD Pharma                                         Legal Statement                                                          Designed by Freeman y la luz